Geographic Atrophy
Conditions
Brief summary
This study is a Phase III, double-masked, multicenter, randomized, sham injection-controlled study evaluating the efficacy and safety of lampalizumab administered by intravitreal injections in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
Interventions
Participants will receive 10 mg dose of lampalizumab administered intravitreally.
A sham injection is a procedure that mimics an intravitreal injection of lampalizumab.
Sponsors
Study design
Eligibility
Inclusion criteria
* Well demarcated area(s) of Geographic Atrophy (GA) secondary to Age-Related Macular Degeneration (AMD) with no evidence of prior or active choroidal neovascularization (CNV) in both eyes
Exclusion criteria
Ocular
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in Geographic Atrophy (GA) Area, as Assessed by Fundus Autofluoresence (FAF) at Week 48 | Baseline, Week 48 | The change in GA lesion area was measured by FAF and analysis of FAF images was performed by the central reading center. A positive change from baseline indicates an increase in size of GA lesion area (worsening; disease progression). |
| Change From Baseline in GA Area in Complement Factor I (CFI) Positive and Negative Participants at Week 48 | Baseline, Week 48 | For CFI profile, positive or negative biomarker status refers to the presence (carrier) or absence of the risk allele at CFI and at least one risk allele at complement factor H (CFH) or risk locus containing both complement component 2 and complement factor B (C2/CFB).The change in GA lesion area was measured by FAF and analysis of FAF images was performed by the central reading center. A positive change from baseline indicates an increase in size of GA lesion area (worsening; disease progression). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in Best Corrected Visual Acuity (BCVA) Score as Assessed by Early Treatment Diabetic Retinopathy Study (ETDRS) Chart at Week 48 | Baseline, Week 48 | BCVA score was based on the number of letters read correctly on the ETDRS visual acuity chart assessed at a starting distance of 4 meters (m). BCVA score testing was performed prior to dilating the eyes. BCVA score ranges from 0 to 100 letters in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). A negative change from baseline indicates a decrease in the visual acuity; disease worsening. The data was collected up to Week 48 instead of Week 96, due to early termination of the study. |
| Percentage of Participants With Less Than 15 Letters Loss From Baseline in BCVA Score at Week 48 | Week 48 | Loss of less than 15 letters from baseline was assessed by the ETDRS chart at a starting distance of 4 meters (m). BCVA was measured using an eye chart and was reported as the number of letters read correctly (ranging from 0 to 100 letters). The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). The data was collected up to Week 48 instead of Week 96, due to early termination of the study. |
| Change From Baseline in Low Luminance Visual Acuity (LLVA) as Assessed by ETDRS Chart Under Low Luminance Conditions at Week 48 | Baseline, Week 48 | The LLVA was measured by placing a 2.0-log-unit neutral density filter over the best correction for that eye and having the participant read the normally illuminated ETDRS chart. The assessment was performed prior to dilating the eyes. LLVA score ranges from 0 to 100 letters in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). The data was collected up to Week 48 instead of Week 96, due to early termination of the study. |
| Percentage of Participants With Less Than 15 Letters Loss From Baseline in LLVA Score at Week 48 | Week 48 | Loss of less than 15 letters from baseline was assessed by the ETDRS chart at a starting distance of 4 m. The data was collected up to Week 48 instead of Week 96, due to early termination of the study. |
| Change From Baseline in Binocular Reading Speed as Assessed by Minnesota Low-Vision Reading Test (MNRead) Charts or Radner Reading Charts at Week 48 | Baseline, Week 48 | MNRead acuity cards were continuous-text reading-acuity cards suitable for measuring the reading acuity and reading speed of normal and low-vision participants. The MNRead acuity cards consisted of single, simple sentences with equal numbers of characters. A stopwatch was used to record time to a tenth of a second. Sentences that could not be read or were not attempted due to vision should be recorded as 0 for time and 10 for errors. The Radner Reading Cards were suitable for measuring reading speed, reading visual acuity, and critical print size. The reading test was stopped when the reading time was longer than 20 seconds or when the participant was making severe errors. A negative change from baseline indicates a decrease in the binocular reading speed; disease worsening. The data was collected up to Week 48 instead of Week 96, due to early termination of the study. |
| Change From Baseline in Number of Absolute Scotomatous Points as Assessed by Mesopic Micrometry at Week 48 | Baseline, Week 48 | Scotomatous points were the testing points on microperimetry examination that were centered on the macula and reported a lack of retinal sensitivity within the range tested, a maximum of 68 points were tested within this range. Higher results indicate expansion of absolute scotoma and higher number of abolute scotomatous points. Mesopic microperimetry assessments were performed post-dilation on the study eye only, and the data was forwarded to the central reading center. The data was collected up to Week 48 instead of Week 96, due to early termination of the study. A positive change from baseline indicates an increase in the number of absolute scotomatous points (more lack of retinal sensitivity); disease worsening. |
| Change From Baseline in Monocular Maximum Reading Speed as Assessed by MNRead Charts or Radner Reading Charts at Week 48 | Baseline, Week 48 | MNRead acuity cards were continuous-text reading-acuity cards suitable for measuring the reading acuity and reading speed of normal and low-vision participants. The MNRead acuity cards consisted of single, simple sentences with equal numbers of characters. A stopwatch was used to record time to a tenth of a second. Sentences that could not be read or were not attempted due to vision should be recorded as 0 for time and 10 for errors. The Radner Reading Cards were suitable for measuring reading speed, reading visual acuity, and critical print size. The reading test was stopped when the reading time was longer than 20 seconds or when the participant was making severe errors. A negative change from baseline indicates a decrease in the monocular reading speed; disease worsening. The data was collected up to Week 48 instead of Week 96, due to early termination of the study. |
| Change From Baseline in National Eye Institute Visual Functioning Questionnaire 25-item (NEI VFQ-25) Version Composite Score at Week 48 | Baseline, Week 48 | NEI-VFQ-25 questionnaire included 25 items based on which overall composite VFQ score and 12 subscales were derived: near activities, distance activities, general health,general vision, ocular pain, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision and peripheral vision. Response to each question converted to 0-100 score. Each subscale, total score=average of items contributing to score. For each subscale and total score, score range: 0 to 100, a higher score represents better functioning. A negative change from baseline indicates a decrease in the visual functioning; disease worsening. The data was collected up to Week 48 instead of Week 96, due to early termination of the study. |
| Change From Baseline in NEI VFQ-25 Near Activity Subscale Score at Week 48 | Baseline, Week 48 | NEI-VFQ-25 questionnaire included 25 items based on which near activities were measured. Near activities are defined as reading ordinary print in newspapers, performing work or hobbies requiring near vision, or finding something on a crowded shelf. Response to each question converted to 0-100 score. Subscale=average of items contributing to score. For this subscale the score range is 0 to 100, a higher score represents better functioning. A negative change from baseline indicates a decrease in the near visual activities; disease worsening. The data was collected up to Week 48 instead of Week 96, due to early termination of the study. |
| Change From Baseline in Mean Functional Reading Independence (FRI) Index at Week 48 | Baseline, Week 48 | The FRI was an interviewer-administered questionnaire with 7 items on functional reading activities most relevant to GA AMD participants. It has one total index score. For each FRI Index reading activity performed in the past 7 days, participants were asked about the extent to which they required vision aids, adjustments in the activity, or help from another participant. Mean FRI Index scores range from 1 to 4, with higher scores indicating greater independence. A negative change from baseline indicates a decrease in the FRI; disease worsening. The data was collected up to Week 48 instead of Week 96, due to early termination of the study. |
| Change From Baseline in NEI VFQ-25 Distance Activity Subscale Score at Week 48 | Baseline, Week 48 | NEI-VFQ-25 questionnaire included 25 items based on which distance activities were measured. Distance activities are defined as reading street signs or names on stores, and going down stairs, steps, or curbs. Response to each question converted to 0-100 score. Subscale=average of items contributing to score. For this subscale the score range is 0 to 100, a higher score represents better functioning. A negative change from baseline indicates a decrease in the distance visual activities; disease worsening. The data was collected up to Week 48 instead of Week 96, due to early termination of the study. |
| Change From Baseline in Mean Macular Sensitivity as Assessed by Mesopic Microperimetry at Week 48 | Baseline, Week 48 | Mesopic microperimetry was used to assess macular sensitivity and assessments were performed post-dilation on the study eye only, and the data was forwarded to the central reading center. A negative change from baseline indicates a decrease in the mean macular sensitivity; disease worsening. The data was collected up to Week 48 instead of Week 96, due to early termination of the study. |
Countries
Argentina, Australia, Austria, Belgium, Canada, Denmark, France, Germany, Hungary, Italy, Mexico, Netherlands, Peru, Poland, Slovakia, Spain, Switzerland, United Kingdom, United States
Participant flow
Recruitment details
A total of 906 participants were randomized to the study from 131 investigation sites across 19 countries. The study was terminated early by the Sponsor due to lack of efficacy.
Pre-assignment details
This study enrolled participants with bilateral Geographic Atrophy (GA) secondary to Age-Related Macular Degeneration (AMD) and no signs of prior or active choroidal neovascularization (CNV), age \>= 50 years with a valid complement factor I (CFI)-profile biomarker result.
Participants by arm
| Arm | Count |
|---|---|
| Sham Comparator Participants received sham comparator once in every 4 weeks (Q4W) or once in every 6 weeks (Q6W) starting at Day 1 visit. | 305 |
| Lampalizumab Q4W Participants received 10 milligrams (mg) dose of lampalizumab administered by intravitreal injections Q4W starting at Day 1 visit. | 298 |
| Lampalizumab Q6W Participants received 10 mg dose of lampalizumab administered by intravitreal injections Q6W starting at Day 1 visit. | 303 |
| Total | 906 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | Adverse Event | 8 | 9 | 8 |
| Overall Study | Death | 5 | 4 | 6 |
| Overall Study | Lost to Follow-up | 3 | 3 | 1 |
| Overall Study | Non-compliance | 0 | 0 | 1 |
| Overall Study | Physician Decision | 1 | 0 | 2 |
| Overall Study | Study Terminated by Sponsor | 98 | 88 | 94 |
| Overall Study | Unspecified Reason | 2 | 5 | 2 |
| Overall Study | Withdrawal by Subject | 25 | 29 | 24 |
Baseline characteristics
| Characteristic | Sham Comparator | Lampalizumab Q4W | Lampalizumab Q6W | Total |
|---|---|---|---|---|
| Age, Continuous | 78.5 years STANDARD_DEVIATION 7.8 | 77.5 years STANDARD_DEVIATION 7.9 | 78.3 years STANDARD_DEVIATION 8.5 | 78.1 years STANDARD_DEVIATION 8.1 |
| Best Corrected Visual Acuity (BCVA) Score as Assessed by Early Treatment Diabetic Retinopathy Study | 65.9 letters STANDARD_DEVIATION 9.9 | 66.1 letters STANDARD_DEVIATION 10 | 66.4 letters STANDARD_DEVIATION 10.1 | 66.2 letters STANDARD_DEVIATION 10 |
| Binocular Reading Speed as Assessed by Minnesota Low-Vision Reading Test or Radner Reading Charts | 106.89 words per minute (wpm) STANDARD_DEVIATION 57.98 | 109.18 words per minute (wpm) STANDARD_DEVIATION 60.14 | 104.22 words per minute (wpm) STANDARD_DEVIATION 62.37 | 106.74 words per minute (wpm) STANDARD_DEVIATION 60.12 |
| GA Area in CFI Negative Participants | 7.864 mm^2 STANDARD_DEVIATION 3.952 | 7.560 mm^2 STANDARD_DEVIATION 3.515 | 7.705 mm^2 STANDARD_DEVIATION 3.975 | 7.710 mm^2 STANDARD_DEVIATION 3.814 |
| GA Area in Complement Factor I (CFI) Positive Participants | 8.015 mm^2 STANDARD_DEVIATION 3.915 | 8.152 mm^2 STANDARD_DEVIATION 4.118 | 8.406 mm^2 STANDARD_DEVIATION 4.399 | 8.190 mm^2 STANDARD_DEVIATION 4.142 |
| Geographic Atrophy (GA) Area, as Assessed by Fundus Autofluoresence (FAF) | 7.953 millimeter square (mm^2) STANDARD_DEVIATION 3.925 | 7.910 millimeter square (mm^2) STANDARD_DEVIATION 3.887 | 8.116 millimeter square (mm^2) STANDARD_DEVIATION 4.236 | 7.993 millimeter square (mm^2) STANDARD_DEVIATION 4.016 |
| Low Luminance Visual Acuity (LLVA) as Assessed by ETDRS Chart Under Low Luminance Conditions | 36.0 letters STANDARD_DEVIATION 15.7 | 36.9 letters STANDARD_DEVIATION 17.8 | 36.2 letters STANDARD_DEVIATION 16.7 | 36.4 letters STANDARD_DEVIATION 16.7 |
| Macular Sensitivity as Assessed by Mesopic Microperimetry | 5.40 decibel (dB) STANDARD_DEVIATION 3.37 | 6.37 decibel (dB) STANDARD_DEVIATION 4.02 | 7.38 decibel (dB) STANDARD_DEVIATION 3.4 | 6.34 decibel (dB) STANDARD_DEVIATION 3.64 |
| Mean Functional Reading Independence (FRI) Index | 2.69 score on a scale STANDARD_DEVIATION 0.83 | 2.71 score on a scale STANDARD_DEVIATION 0.79 | 2.70 score on a scale STANDARD_DEVIATION 0.82 | 2.70 score on a scale STANDARD_DEVIATION 0.81 |
| Monocular Maximum Reading Speed as Assessed by MNRead Charts or Radner Reading Charts | 80.89 wpm STANDARD_DEVIATION 52.95 | 85.18 wpm STANDARD_DEVIATION 54.55 | 79.49 wpm STANDARD_DEVIATION 54.23 | 81.82 wpm STANDARD_DEVIATION 53.89 |
| National Eye Institute Visual Functioning Questionnaire 25-item (NEI VFQ-25) Version Composite Score | 66.16 score on a scale STANDARD_DEVIATION 17.33 | 64.80 score on a scale STANDARD_DEVIATION 16.12 | 65.19 score on a scale STANDARD_DEVIATION 17.27 | 65.38 score on a scale STANDARD_DEVIATION 16.91 |
| NEI VFQ-25 Distance Activity Subscale Score | 62.86 score on a scale STANDARD_DEVIATION 21.46 | 60.97 score on a scale STANDARD_DEVIATION 20.48 | 62.10 score on a scale STANDARD_DEVIATION 22.16 | 61.98 score on a scale STANDARD_DEVIATION 21.37 |
| NEI VFQ-25 Near Activity Subscale Score | 54.98 score on a scale STANDARD_DEVIATION 20.98 | 53.78 score on a scale STANDARD_DEVIATION 20.56 | 53.67 score on a scale STANDARD_DEVIATION 22.21 | 54.14 score on a scale STANDARD_DEVIATION 21.25 |
| Number of Absolute Scotomatous Points as Assessed by Mesopic Micrometry | 29.1 absolute scotomatous points STANDARD_DEVIATION 16.8 | 25.2 absolute scotomatous points STANDARD_DEVIATION 13.4 | 20.5 absolute scotomatous points STANDARD_DEVIATION 13.4 | 25.1 absolute scotomatous points STANDARD_DEVIATION 15.1 |
| Race/Ethnicity, Customized American Indian or Alaska Native | 0 Participants | 1 Participants | 1 Participants | 2 Participants |
| Race/Ethnicity, Customized Hispanic or Latino | 20 Participants | 17 Participants | 18 Participants | 55 Participants |
| Race/Ethnicity, Customized Multiple | 0 Participants | 0 Participants | 1 Participants | 1 Participants |
| Race/Ethnicity, Customized Native Hawaiian or other Pacific Islander | 0 Participants | 1 Participants | 0 Participants | 1 Participants |
| Race/Ethnicity, Customized Not Hispanic or Latino | 279 Participants | 278 Participants | 282 Participants | 839 Participants |
| Race/Ethnicity, Customized Not Stated | 2 Participants | 3 Participants | 1 Participants | 6 Participants |
| Race/Ethnicity, Customized Unknown | 4 Participants | 2 Participants | 6 Participants | 11 Participants |
| Race/Ethnicity, Customized White | 302 Participants | 294 Participants | 295 Participants | 891 Participants |
| Sex: Female, Male Female | 186 Participants | 182 Participants | 185 Participants | 553 Participants |
| Sex: Female, Male Male | 119 Participants | 116 Participants | 118 Participants | 353 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 6 / 300 | 5 / 298 | 6 / 303 |
| other Total, other adverse events | 221 / 300 | 239 / 298 | 232 / 303 |
| serious Total, serious adverse events | 97 / 300 | 118 / 298 | 108 / 303 |
Outcome results
Change From Baseline in GA Area in Complement Factor I (CFI) Positive and Negative Participants at Week 48
For CFI profile, positive or negative biomarker status refers to the presence (carrier) or absence of the risk allele at CFI and at least one risk allele at complement factor H (CFH) or risk locus containing both complement component 2 and complement factor B (C2/CFB).The change in GA lesion area was measured by FAF and analysis of FAF images was performed by the central reading center. A positive change from baseline indicates an increase in size of GA lesion area (worsening; disease progression).
Time frame: Baseline, Week 48
Population: ITT population included all the participants who were randomized to the study. The analysis was done specifically for CFI-positive and negative participants. Number analyzed for each row signifies the participants evaluated for specified categories for each reporting group.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Sham Comparator | Change From Baseline in GA Area in Complement Factor I (CFI) Positive and Negative Participants at Week 48 | CFI-Positive Participants | 2.067 mm^2 | Standard Error 0.086 |
| Sham Comparator | Change From Baseline in GA Area in Complement Factor I (CFI) Positive and Negative Participants at Week 48 | CFI-Negative Participants | 2.006 mm^2 | Standard Error 0.103 |
| Lampalizumab Q4W | Change From Baseline in GA Area in Complement Factor I (CFI) Positive and Negative Participants at Week 48 | CFI-Positive Participants | 2.045 mm^2 | Standard Error 0.089 |
| Lampalizumab Q4W | Change From Baseline in GA Area in Complement Factor I (CFI) Positive and Negative Participants at Week 48 | CFI-Negative Participants | 1.974 mm^2 | Standard Error 0.105 |
| Lampalizumab Q6W | Change From Baseline in GA Area in Complement Factor I (CFI) Positive and Negative Participants at Week 48 | CFI-Positive Participants | 2.144 mm^2 | Standard Error 0.087 |
| Lampalizumab Q6W | Change From Baseline in GA Area in Complement Factor I (CFI) Positive and Negative Participants at Week 48 | CFI-Negative Participants | 2.012 mm^2 | Standard Error 0.104 |
Change From Baseline in Geographic Atrophy (GA) Area, as Assessed by Fundus Autofluoresence (FAF) at Week 48
The change in GA lesion area was measured by FAF and analysis of FAF images was performed by the central reading center. A positive change from baseline indicates an increase in size of GA lesion area (worsening; disease progression).
Time frame: Baseline, Week 48
Population: ITT population included all the participants who were randomized to the study. Participants analyzed in this outcome measure were those included in Mixed-effect model repeated measures (MMRM) analysis.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Sham Comparator | Change From Baseline in Geographic Atrophy (GA) Area, as Assessed by Fundus Autofluoresence (FAF) at Week 48 | 2.035 millimeter square (mm^2) | Standard Error 0.066 |
| Lampalizumab Q4W | Change From Baseline in Geographic Atrophy (GA) Area, as Assessed by Fundus Autofluoresence (FAF) at Week 48 | 2.016 millimeter square (mm^2) | Standard Error 0.068 |
| Lampalizumab Q6W | Change From Baseline in Geographic Atrophy (GA) Area, as Assessed by Fundus Autofluoresence (FAF) at Week 48 | 2.086 millimeter square (mm^2) | Standard Error 0.067 |
Change From Baseline in Best Corrected Visual Acuity (BCVA) Score as Assessed by Early Treatment Diabetic Retinopathy Study (ETDRS) Chart at Week 48
BCVA score was based on the number of letters read correctly on the ETDRS visual acuity chart assessed at a starting distance of 4 meters (m). BCVA score testing was performed prior to dilating the eyes. BCVA score ranges from 0 to 100 letters in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). A negative change from baseline indicates a decrease in the visual acuity; disease worsening. The data was collected up to Week 48 instead of Week 96, due to early termination of the study.
Time frame: Baseline, Week 48
Population: ITT population included all the participants who were randomized to the study. Participants analyzed in this outcome measure were those included in MMRM analysis.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Sham Comparator | Change From Baseline in Best Corrected Visual Acuity (BCVA) Score as Assessed by Early Treatment Diabetic Retinopathy Study (ETDRS) Chart at Week 48 | -4.5 letters | Standard Error 0.6 |
| Lampalizumab Q4W | Change From Baseline in Best Corrected Visual Acuity (BCVA) Score as Assessed by Early Treatment Diabetic Retinopathy Study (ETDRS) Chart at Week 48 | -3.4 letters | Standard Error 0.6 |
| Lampalizumab Q6W | Change From Baseline in Best Corrected Visual Acuity (BCVA) Score as Assessed by Early Treatment Diabetic Retinopathy Study (ETDRS) Chart at Week 48 | -4.6 letters | Standard Error 0.6 |
Change From Baseline in Binocular Reading Speed as Assessed by Minnesota Low-Vision Reading Test (MNRead) Charts or Radner Reading Charts at Week 48
MNRead acuity cards were continuous-text reading-acuity cards suitable for measuring the reading acuity and reading speed of normal and low-vision participants. The MNRead acuity cards consisted of single, simple sentences with equal numbers of characters. A stopwatch was used to record time to a tenth of a second. Sentences that could not be read or were not attempted due to vision should be recorded as 0 for time and 10 for errors. The Radner Reading Cards were suitable for measuring reading speed, reading visual acuity, and critical print size. The reading test was stopped when the reading time was longer than 20 seconds or when the participant was making severe errors. A negative change from baseline indicates a decrease in the binocular reading speed; disease worsening. The data was collected up to Week 48 instead of Week 96, due to early termination of the study.
Time frame: Baseline, Week 48
Population: ITT population included all the participants who were randomized to the study. Participants analyzed in this outcome measure were those included in MMRM analysis.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Sham Comparator | Change From Baseline in Binocular Reading Speed as Assessed by Minnesota Low-Vision Reading Test (MNRead) Charts or Radner Reading Charts at Week 48 | -18.97 words per minute (wpm) | Standard Error 2.37 |
| Lampalizumab Q4W | Change From Baseline in Binocular Reading Speed as Assessed by Minnesota Low-Vision Reading Test (MNRead) Charts or Radner Reading Charts at Week 48 | -13.32 words per minute (wpm) | Standard Error 2.47 |
| Lampalizumab Q6W | Change From Baseline in Binocular Reading Speed as Assessed by Minnesota Low-Vision Reading Test (MNRead) Charts or Radner Reading Charts at Week 48 | -19.96 words per minute (wpm) | Standard Error 2.44 |
Change From Baseline in Low Luminance Visual Acuity (LLVA) as Assessed by ETDRS Chart Under Low Luminance Conditions at Week 48
The LLVA was measured by placing a 2.0-log-unit neutral density filter over the best correction for that eye and having the participant read the normally illuminated ETDRS chart. The assessment was performed prior to dilating the eyes. LLVA score ranges from 0 to 100 letters in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). The data was collected up to Week 48 instead of Week 96, due to early termination of the study.
Time frame: Baseline, Week 48
Population: ITT population included all the participants who were randomized to the study. Participants analyzed in this outcome measure were those included in MMRM analysis.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Sham Comparator | Change From Baseline in Low Luminance Visual Acuity (LLVA) as Assessed by ETDRS Chart Under Low Luminance Conditions at Week 48 | -3.0 letters | Standard Error 0.7 |
| Lampalizumab Q4W | Change From Baseline in Low Luminance Visual Acuity (LLVA) as Assessed by ETDRS Chart Under Low Luminance Conditions at Week 48 | -2.4 letters | Standard Error 0.7 |
| Lampalizumab Q6W | Change From Baseline in Low Luminance Visual Acuity (LLVA) as Assessed by ETDRS Chart Under Low Luminance Conditions at Week 48 | -2.7 letters | Standard Error 0.7 |
Change From Baseline in Mean Functional Reading Independence (FRI) Index at Week 48
The FRI was an interviewer-administered questionnaire with 7 items on functional reading activities most relevant to GA AMD participants. It has one total index score. For each FRI Index reading activity performed in the past 7 days, participants were asked about the extent to which they required vision aids, adjustments in the activity, or help from another participant. Mean FRI Index scores range from 1 to 4, with higher scores indicating greater independence. A negative change from baseline indicates a decrease in the FRI; disease worsening. The data was collected up to Week 48 instead of Week 96, due to early termination of the study.
Time frame: Baseline, Week 48
Population: ITT population included all the participants who were randomized to the study. Participants analyzed in this outcome measure were those included in MMRM analysis.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Sham Comparator | Change From Baseline in Mean Functional Reading Independence (FRI) Index at Week 48 | -0.06 score on a scale | Standard Error 0.04 |
| Lampalizumab Q4W | Change From Baseline in Mean Functional Reading Independence (FRI) Index at Week 48 | -0.13 score on a scale | Standard Error 0.04 |
| Lampalizumab Q6W | Change From Baseline in Mean Functional Reading Independence (FRI) Index at Week 48 | -0.15 score on a scale | Standard Error 0.04 |
Change From Baseline in Mean Macular Sensitivity as Assessed by Mesopic Microperimetry at Week 48
Mesopic microperimetry was used to assess macular sensitivity and assessments were performed post-dilation on the study eye only, and the data was forwarded to the central reading center. A negative change from baseline indicates a decrease in the mean macular sensitivity; disease worsening. The data was collected up to Week 48 instead of Week 96, due to early termination of the study.
Time frame: Baseline, Week 48
Population: The microperimetry analysis population consisted of all participants who met the microperimetry eligibility criteria assessed by the reading center (participants at selected sites only; participants grouped according to treatment assigned at randomization). Participants analyzed in this outcome measure were those included in MMRM analysis.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Sham Comparator | Change From Baseline in Mean Macular Sensitivity as Assessed by Mesopic Microperimetry at Week 48 | -1.61 decibel (dB) | Standard Error 0.33 |
| Lampalizumab Q4W | Change From Baseline in Mean Macular Sensitivity as Assessed by Mesopic Microperimetry at Week 48 | -1.33 decibel (dB) | Standard Error 0.34 |
| Lampalizumab Q6W | Change From Baseline in Mean Macular Sensitivity as Assessed by Mesopic Microperimetry at Week 48 | -2.24 decibel (dB) | Standard Error 0.35 |
Change From Baseline in Monocular Maximum Reading Speed as Assessed by MNRead Charts or Radner Reading Charts at Week 48
MNRead acuity cards were continuous-text reading-acuity cards suitable for measuring the reading acuity and reading speed of normal and low-vision participants. The MNRead acuity cards consisted of single, simple sentences with equal numbers of characters. A stopwatch was used to record time to a tenth of a second. Sentences that could not be read or were not attempted due to vision should be recorded as 0 for time and 10 for errors. The Radner Reading Cards were suitable for measuring reading speed, reading visual acuity, and critical print size. The reading test was stopped when the reading time was longer than 20 seconds or when the participant was making severe errors. A negative change from baseline indicates a decrease in the monocular reading speed; disease worsening. The data was collected up to Week 48 instead of Week 96, due to early termination of the study.
Time frame: Baseline, Week 48
Population: ITT population included all the participants who were randomized to the study. Participants analyzed in this outcome measure were those included in MMRM analysis.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Sham Comparator | Change From Baseline in Monocular Maximum Reading Speed as Assessed by MNRead Charts or Radner Reading Charts at Week 48 | -19.63 wpm | Standard Error 2.41 |
| Lampalizumab Q4W | Change From Baseline in Monocular Maximum Reading Speed as Assessed by MNRead Charts or Radner Reading Charts at Week 48 | -17.91 wpm | Standard Error 2.49 |
| Lampalizumab Q6W | Change From Baseline in Monocular Maximum Reading Speed as Assessed by MNRead Charts or Radner Reading Charts at Week 48 | -18.16 wpm | Standard Error 2.47 |
Change From Baseline in National Eye Institute Visual Functioning Questionnaire 25-item (NEI VFQ-25) Version Composite Score at Week 48
NEI-VFQ-25 questionnaire included 25 items based on which overall composite VFQ score and 12 subscales were derived: near activities, distance activities, general health,general vision, ocular pain, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision and peripheral vision. Response to each question converted to 0-100 score. Each subscale, total score=average of items contributing to score. For each subscale and total score, score range: 0 to 100, a higher score represents better functioning. A negative change from baseline indicates a decrease in the visual functioning; disease worsening. The data was collected up to Week 48 instead of Week 96, due to early termination of the study.
Time frame: Baseline, Week 48
Population: ITT population included all the participants who were randomized to the study. Participants analyzed in this outcome measure were those included in MMRM analysis.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Sham Comparator | Change From Baseline in National Eye Institute Visual Functioning Questionnaire 25-item (NEI VFQ-25) Version Composite Score at Week 48 | -1.31 scores on a scale | Standard Error 0.71 |
| Lampalizumab Q4W | Change From Baseline in National Eye Institute Visual Functioning Questionnaire 25-item (NEI VFQ-25) Version Composite Score at Week 48 | -1.66 scores on a scale | Standard Error 0.72 |
| Lampalizumab Q6W | Change From Baseline in National Eye Institute Visual Functioning Questionnaire 25-item (NEI VFQ-25) Version Composite Score at Week 48 | -2.87 scores on a scale | Standard Error 0.7 |
Change From Baseline in NEI VFQ-25 Distance Activity Subscale Score at Week 48
NEI-VFQ-25 questionnaire included 25 items based on which distance activities were measured. Distance activities are defined as reading street signs or names on stores, and going down stairs, steps, or curbs. Response to each question converted to 0-100 score. Subscale=average of items contributing to score. For this subscale the score range is 0 to 100, a higher score represents better functioning. A negative change from baseline indicates a decrease in the distance visual activities; disease worsening. The data was collected up to Week 48 instead of Week 96, due to early termination of the study.
Time frame: Baseline, Week 48
Population: ITT population included all the participants who were randomized to the study. Participants analyzed in this outcome measure were those included in MMRM analysis.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Sham Comparator | Change From Baseline in NEI VFQ-25 Distance Activity Subscale Score at Week 48 | -2.03 score on a scale | Standard Error 0.99 |
| Lampalizumab Q4W | Change From Baseline in NEI VFQ-25 Distance Activity Subscale Score at Week 48 | -1.04 score on a scale | Standard Error 1 |
| Lampalizumab Q6W | Change From Baseline in NEI VFQ-25 Distance Activity Subscale Score at Week 48 | -3.62 score on a scale | Standard Error 0.97 |
Change From Baseline in NEI VFQ-25 Near Activity Subscale Score at Week 48
NEI-VFQ-25 questionnaire included 25 items based on which near activities were measured. Near activities are defined as reading ordinary print in newspapers, performing work or hobbies requiring near vision, or finding something on a crowded shelf. Response to each question converted to 0-100 score. Subscale=average of items contributing to score. For this subscale the score range is 0 to 100, a higher score represents better functioning. A negative change from baseline indicates a decrease in the near visual activities; disease worsening. The data was collected up to Week 48 instead of Week 96, due to early termination of the study.
Time frame: Baseline, Week 48
Population: ITT population included all the participants who were randomized to the study. Participants analyzed in this outcome measure were those included in MMRM analysis.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Sham Comparator | Change From Baseline in NEI VFQ-25 Near Activity Subscale Score at Week 48 | -2.12 score on a scale | Standard Error 0.93 |
| Lampalizumab Q4W | Change From Baseline in NEI VFQ-25 Near Activity Subscale Score at Week 48 | -2.35 score on a scale | Standard Error 0.94 |
| Lampalizumab Q6W | Change From Baseline in NEI VFQ-25 Near Activity Subscale Score at Week 48 | -4.06 score on a scale | Standard Error 0.92 |
Change From Baseline in Number of Absolute Scotomatous Points as Assessed by Mesopic Micrometry at Week 48
Scotomatous points were the testing points on microperimetry examination that were centered on the macula and reported a lack of retinal sensitivity within the range tested, a maximum of 68 points were tested within this range. Higher results indicate expansion of absolute scotoma and higher number of abolute scotomatous points. Mesopic microperimetry assessments were performed post-dilation on the study eye only, and the data was forwarded to the central reading center. The data was collected up to Week 48 instead of Week 96, due to early termination of the study. A positive change from baseline indicates an increase in the number of absolute scotomatous points (more lack of retinal sensitivity); disease worsening.
Time frame: Baseline, Week 48
Population: The microperimetry analysis population consisted of all participants who met the microperimetry eligibility criteria assessed by the reading center (participants at selected sites only; participants grouped according to treatment assigned at randomization). Participants analyzed in this outcome measure were those included in MMRM analysis.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Sham Comparator | Change From Baseline in Number of Absolute Scotomatous Points as Assessed by Mesopic Micrometry at Week 48 | 8.3 absolute scotomatous points | Standard Error 1.7 |
| Lampalizumab Q4W | Change From Baseline in Number of Absolute Scotomatous Points as Assessed by Mesopic Micrometry at Week 48 | 8.1 absolute scotomatous points | Standard Error 1.8 |
| Lampalizumab Q6W | Change From Baseline in Number of Absolute Scotomatous Points as Assessed by Mesopic Micrometry at Week 48 | 8.3 absolute scotomatous points | Standard Error 1.8 |
Percentage of Participants With Less Than 15 Letters Loss From Baseline in BCVA Score at Week 48
Loss of less than 15 letters from baseline was assessed by the ETDRS chart at a starting distance of 4 meters (m). BCVA was measured using an eye chart and was reported as the number of letters read correctly (ranging from 0 to 100 letters). The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). The data was collected up to Week 48 instead of Week 96, due to early termination of the study.
Time frame: Week 48
Population: ITT population included all the participants who were randomized to the study. Reported here is the number of participants for whom data were collected.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Sham Comparator | Percentage of Participants With Less Than 15 Letters Loss From Baseline in BCVA Score at Week 48 | 85.8 percentage of participants |
| Lampalizumab Q4W | Percentage of Participants With Less Than 15 Letters Loss From Baseline in BCVA Score at Week 48 | 88.8 percentage of participants |
| Lampalizumab Q6W | Percentage of Participants With Less Than 15 Letters Loss From Baseline in BCVA Score at Week 48 | 87.0 percentage of participants |
Percentage of Participants With Less Than 15 Letters Loss From Baseline in LLVA Score at Week 48
Loss of less than 15 letters from baseline was assessed by the ETDRS chart at a starting distance of 4 m. The data was collected up to Week 48 instead of Week 96, due to early termination of the study.
Time frame: Week 48
Population: ITT population included all the participants who were randomized to the study. Reported here is the number of participants for whom data were collected.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Sham Comparator | Percentage of Participants With Less Than 15 Letters Loss From Baseline in LLVA Score at Week 48 | 86.8 percentage of participants |
| Lampalizumab Q4W | Percentage of Participants With Less Than 15 Letters Loss From Baseline in LLVA Score at Week 48 | 85.3 percentage of participants |
| Lampalizumab Q6W | Percentage of Participants With Less Than 15 Letters Loss From Baseline in LLVA Score at Week 48 | 86.6 percentage of participants |